Clinical trials: Hepatic Function
Arthritis, Rheumatoid
SB-681323-Methotrexate Interaction Study
SB-681323 is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA. Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity.
- Trial name
- NCT00419809
- Testing
- SB-681323 oral tablets
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Cirrhosis
Evaluation of Hepatic Function Using Gadoxetic Acid Enhanced MRI
Liver function is a key factor that can help predict the clinical outcome in patients with cirrhosis. Traditionally, liver function was measured using either indocyanine green (ICG) or other radionucleotides.
- Trial name
- NCT02854371
- Testing
- gadoxetic acid enhanced liver MRI, ICG R15
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Seoul National University Hospital
Autoimmune Liver Disease
Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Therapy of Autoimmune Liver Disease
This study was a retrospective clinical observation cohort study. All patients with autoimmune liver disease treated with glycyrrhizic acid preparations in the Department of Liver Diseases, Department of Liver Diseases, Beijing…
- Trial name
- NCT04028869
- Testing
- Glycyrrhizic acid preparation
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Ditan Hospital
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable…
- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
- Trial name
- GDFATHERHCC01 (NCT07219459)
- Testing
- Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 104 people
- Sponsor
- CatalYm GmbH
Hepatic Insufficiency
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m2 can take part.
- Trial name
- NCT06957756
- Testing
- BI 1584862
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
This phase I trial is studying the side effects and best dose of sorafenib in treating patients with metastatic or unresectable solid tumors, multiple myeloma, or non-Hodgkin's lymphoma with or without impaired liver or kidney…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00118170
- Testing
- sorafenib tosylate, pharmacological study
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Hepatic Impairment
Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
This is an open-label, single-dose study designed to assess the pharmacokinetics and safety of ABT-493 and/or ABT-530 in subjects with impaired hepatic function and compare them to those in subjects with normal hepatic function.
- Trial name
- NCT02296905
- Testing
- ABT-493, ABT-530
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Fatty Liver
Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
In this initial investigator-initiated retrospective study, aim to analyze the enhanced liver fibrosis (ELF) scores in this high-risk population for NAFLD/nonalcoholic steatohepatitis(NASH)-related fibrosis.
- Trial name
- NCT06225193
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Methodist Health System
Acute Liver Failure
ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF
The artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary…
- Trial name
- NCT07329036
- Testing
- The artificial liver support system (ALSS) - DPMAS/TPE
- Where
- Czechia
- Volunteers
- 25 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Hepatic Impairment, Healthy
Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function
The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe…
- Trial name
- NCT01732263
- Testing
- SSP-004184
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Shire
Liver Health
Dietary Intervention Study on Liver Health in Young Adults
This prospective randomized dietary intervention study investigates the effects of two dietary approaches on liver health in young adults over a 12-week period.
- Trial name
- NCT07786831
- Testing
- Mediterranean Diet Intervention, General Healthy Diet Intervention
- Where
- Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hochschule Campus Wien (University of Applied Sciences Campus Vienna)
Hepatic Insufficiency
A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems
This study is open to people with and without liver problems. People can join the study if they are 18 to 79 years of age and have a body mass index (BMI) between 18.5 and 35 kg/m2.
- Trial name
- NCT05731895
- Testing
- Iclepertin
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Diabetes Mellitus, Type 2
School-Based Program On Metabolic Disease
Mexico occupies the first place worldwide in childhood obesity. Its urban and indigenous communities present different levels of westernization which have triggered different epidemiological diseases.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Cardiovascular Function, Kidney Diseases
- Trial name
- NCT03768245
- Testing
- Health Education and Physical activity program, Nutrition Program
- Where
- Mexico
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Epworth Sleepiness Scale, Glycemic Control
LAP-BAND Observational Cohort
To prospectively observe the association of the LAP-BAND procedure on quality of life, anthropometric, metabolic and biochemical parameters in morbidly obese patients when performed by experienced US surgeons.
- Conditions
- Epworth Sleepiness Scale, Glycemic Control, Liver Function, Inflammation
- Trial name
- NCT00283972
- Testing
- LAP-BAND System
- Volunteers
- 240 people
- Sponsor
- Inamed
Living Donor Liver Transplantation
Impact of Splenic Artery Ligation in LDLT for Patients With Portal Hypertension
In this study, the investigators aim to prove that performing splenic artery ligation in living donor liver transplantation for patients with portal hypertension is beneficial for early graft function postoperatively.
- Trial name
- NCT04988100
- Testing
- splenic artery ligation, No intervention
- Volunteers
- 30 people
- Sponsor
- Assiut University
Gaucher Disease
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
Primary Objective: To study the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of eliglustat. Secondary Objective: To assess the tolerability of eliglustat tartrate given as a single dose in subjects…
- Trial name
- NCT02536911
- Testing
- eliglustat
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Hepatic Impairment, Healthy Participants
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
The purpose of this study is to characterize the effect of hepatic impairment on the pharmacokinetic(s) (PK) of PF-06651600 following administration of multiple once daily doses of PF-06651600.
- Trial name
- NCT04016077
- Testing
- PF-06651600 30 mg
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatic Insufficiency
A Study of Tirzepatide in Participants With Impaired Liver Function
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.
- Trial name
- NCT03940742
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatic Insufficiency, Healthy
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female…
- Trial name
- NCT05440344
- Testing
- Imlunestrant
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Chronic Liver Disease, Acute Derangement of Liver Function
Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
Chronic liver disease including liver cirrhosis is still associated with high mortality, although advancement of medical management and transplantation.
- Trial name
- NCT02650011
- Testing
- Acute deterioration of liver function
- Where
- South Korea
- Volunteers
- 1,520 people
- Sponsor
- Chuncheon Sacred Heart Hospital